Drug · DIN 02529254
TRURAPI
VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since November 3, 2022; first marketed November 3, 2022.
- Drug Identification Number (DIN)
- 02529254
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Solution
- Route
- Intravenous; Subcutaneous
- Therapeutic class (ATC)
- Insulin aspart A10AB05
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| INSULIN ASPART | 100 UNIT | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 20, 2022: NOC 28634Supplement to a New Drug Submission (SNDS) · New route of administration and new presentation
Other DINs named TRURAPI
- DIN 02506564 · Marketed
- DIN 02506572 · Marketed